LL-37: What the Research Shows About This Human Antimicrobial Peptide

What it is

Before antibiotics, animals had antimicrobial peptides: short, charged molecules that stick to bacterial membranes and tear them open. Humans make exactly one of the cathelicidin family, a 37-amino-acid peptide that starts with two leucines, hence LL-37. Skin cells, gut lining, lung lining, and white blood cells all produce it, and levels rise when the body senses infection or injury.

It is one of the few peptides on this site that is not a copy of a hormone. It is a weapon, and a messenger that calls other immune cells to the fight.

What it is studied for

Killing bacteria and fungi, including antibiotic-resistant ones. Breaking up biofilms, the protective slime bacteria build on wounds, catheters, and implants. Healing skin wounds. Immune signaling, and, on the dark side, its role in inflammatory skin and autoimmune diseases.

What the evidence actually shows

In the lab

LL-37 kills a wide range of bacteria, both gram-positive and gram-negative, including some resistant strains, by inserting into their membranes; it also has activity against some fungi and viruses (Vandamme et al., 2012). It prevents Pseudomonas aeruginosa, a notorious wound and lung pathogen, from forming biofilms at concentrations well below what it takes to kill the bacteria outright, and it breaks up biofilms that already exist (Overhage et al., 2008). Biofilm infections are among the hardest to treat, which is why this finding gets attention.

In animals and human tissue

In skin wounds, LL-37 helps the top layer of skin grow back over the wound, draws in repair cells, and encourages new blood vessels. Human chronic ulcers, the wounds that sit open for months, are short of LL-37 in their edges, and adding it back sped closure in animal models (Heilborn et al., 2003). Early human trials of a topical LL-37 gel on venous leg ulcers have been run; they are small and preliminary.

The other edge

LL-37 is also a driver of inflammation. In psoriasis it binds the body’s own DNA and triggers an immune reaction against skin; in rosacea excess LL-37 fragments cause the redness; in lupus it feeds the autoimmune loop (Kahlenberg & Kaplan, 2013). In cancer, it helps some tumors grow and suppresses others. A peptide the body regulates this carefully is not one to add casually.

In humans, injected

Nothing. No trial has given LL-37 systemically to a person. The topical work is the only human data.

From user reports

People inject it for chronic infections, gut problems, and Lyme-type complaints. Some report improvement; a notable number report strong injection-site reactions, flu-like inflammation, and flares of skin conditions, which is consistent with what the peptide does. None of it is measured.

How it works

LL-37 carries a positive charge and folds into a helix. Bacterial membranes are negatively charged, so it binds them, inserts, and disrupts them until the cell leaks and dies. Human cell membranes are built differently and are mostly spared, at normal concentrations. Beyond killing, it signals: it recruits immune cells, promotes blood-vessel growth, and modulates inflammation up or down depending on context. Vitamin D switches on the gene that makes it, which is one reason vitamin D matters for infection defense.

How it is used in studies

Lab and animal studies apply it directly to bacteria or wounds. Users inject 100 to 200 micrograms under the skin daily for a few weeks, or apply it topically. No human dosing data exists for injection. See the storage guide.

Side effects and unknowns

Reported: injection-site pain and redness, flu-like symptoms, and flares of psoriasis or rosacea. The unknowns are large. At high concentrations LL-37 damages human cells too. It can trigger autoimmune-type reactions. It can promote tumor growth in some tissues. And no one has measured what happens when it is injected into a person. See the safety guide.

How it compares

• Thymosin alpha-1: works through immune cells rather than killing microbes, and has decades of human trials.
• KPV: an anti-inflammatory fragment with mild antimicrobial activity in a dish.
• BPC-157 and TB-500: healing peptides with animal data and no direct antimicrobial effect.
• Vitamin D: raises your own LL-37 production, with far more human evidence than the peptide itself.

Legal status

Not approved for any use anywhere. Sold as a research chemical. Not on the WADA Prohibited List.

Bottom line

LL-37 is a genuinely important molecule with a real research program aimed at wound gels and anti-biofilm coatings. Injecting it is a different proposition: a potent inflammatory signal with no human data, a known role in autoimmune disease, and user reports that match the biology. If you want more LL-37, the evidence-backed route is checking your vitamin D.

References

1. Vandamme D, et al. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. PubMed
2. Overhage J, et al. (2008). Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. PubMed
3. Heilborn JD, et al. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. PubMed
4. Kahlenberg JM, Kaplan MJ. (2013). Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. PubMed

See also

• Peptide
  BPC-157: What the Research Actually Shows About This Healing Peptide

  A plain review of the animal research on BPC-157, what it suggests about healing, and why none of it has been confirmed in people.

• Peptide
  GHK-Cu (Copper Peptide): Research, Mechanism, and Evidence for Tissue Repair

  GHK-Cu is a copper-carrying peptide your body makes naturally, studied mainly as a skin cream for aging skin and, in animals, for wound healing.

• Peptide
  KPV: What the Research Shows About This Anti-Inflammatory Tripeptide

  KPV is the last three amino acids of alpha-MSH, a hormone that both tans skin and calms inflammation. The fragment keeps the calming and drops the tanning. It reduced gut and skin inflammation in mice; no human trial exists.